Last reviewed · How we verify
BEACOPP escalated
BEACOPP escalated is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at escalated doses to kill rapidly dividing cancer cells.
BEACOPP escalated is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at escalated doses to kill rapidly dividing cancer cells. Used for Hodgkin lymphoma, advanced stages (Phase 3 development).
At a glance
| Generic name | BEACOPP escalated |
|---|---|
| Sponsor | University of Cologne |
| Drug class | Polychemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BEACOPP escalated is an intensified polychemotherapy combination used primarily in Hodgkin lymphoma. The regimen works through multiple mechanisms: alkylating agents (cyclophosphamide, procarbazine) cross-link DNA, topoisomerase inhibitors (etoposide) prevent DNA repair, anthracyclines (doxorubicin) intercalate DNA and generate reactive oxygen species, and vinca alkaloids (vincristine) disrupt microtubule formation. The 'escalated' designation refers to dose intensification compared to standard BEACOPP.
Approved indications
- Hodgkin lymphoma, advanced stages (Phase 3 development)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Alopecia
- Infection
- Cardiotoxicity
- Secondary malignancy (long-term)
Key clinical trials
- FIL Study on ABVD DD-DI as Upfront Therapy in HL. (PHASE3)
- Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma (PHASE3)
- HD21 for Advanced Stages (PHASE3)
- Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (PHASE3)
- Prognostic Significance of ctDNA in HL
- S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma (PHASE2)
- Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma (PHASE2)
- Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BEACOPP escalated CI brief — competitive landscape report
- BEACOPP escalated updates RSS · CI watch RSS
- University of Cologne portfolio CI